Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct
recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly …

The past several years have seen tremendous advances in the engineering of immune
effector cells as therapy for cancer. While chimeric antigen receptors (CARs) have been …

Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …

Despite considerable progress has been achieved in the treatment of acute myeloid
leukemia over the past decades, relapse remains a major problem. Novel therapeutic …

Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK
cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of …

Allogeneic stem cell transplantation is an effective treatment for high-risk myeloid
malignancies, but relapse remains the major post-transplantation cause of treatment failure …

Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating
patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell …

In the allogeneic environment, the potential effects of TCR signaling on the efficacy of CAR
could affect the clinical responses with the use of donor-derived CAR T cells. Better …

Consolidation therapies for children with intermediate-or high-risk acute myeloid leukemia
(AML) are urgently needed to achieve higher cure rates while limiting therapy-related …

In recent years, the relevance of the immune system to fight cancer has led to the
development of immunotherapy, including the adoptive cell transfer of immune cells, such as …